Tactogen is a mission-based and research-driven pharmatech company that uses machine learning and targeted assays to identify promising new medicines and new treatments. We seek to understand and leverage the ability of novel small molecules to improve health in a variety of contexts, including mental health and neurological problems.

Much of our activity centers on evaluating novel candidate molecules. Evaluation includes in vitro functional measures of mechanisms and in vivo estimation of therapeutic potential. We maximize our productivity and impact by collaborating with select academic partners and contract research organizations.

Tactogen is dedicated to creating innovative, first-in-class medicines. The medicines we are developing represent more than isolated opportunities or single indications — we see them as representing broader platforms that enable us to uncover the factors that are central to sustained wellness. We believe that this work has potential to help most people. That’s our goal: Effective Prescription Mental Wellness. For Everyone.

We have filed over a dozen patent applications on groups of novel chemical entities as of late 2023, with the earliest beginning to convert into awarded patents. And we continue to make new discoveries. Our IP includes molecules, drug combinations, treatment methods, and pharmaceutical preparations. These primarily focus on the goal of enabling safer, gentler take-home prescription mental health medicines. We believe this will be a key to effective and accessible mental wellness for millions of people.

Because we focus on gentler molecules, we are necessarily discovering new molecules outside this area of focus that possess therapeutic promise. When these molecules offer potential significant advantages over available options, we evaluate developing them, potentially in partnership with other organizations.